Form 4: Milestone Pharma CEO Reports Significant Equity Transactions

Milestone Pharmaceuticals Inc.'s President and CEO, Joseph Oliveto, reported the vesting of performance and restricted stock units, alongside related sell-to-cover transactions for tax liabilities.

Summary

• Joseph Oliveto, President and CEO of Milestone Pharmaceuticals Inc. (MIST), reported multiple equity transactions.
• Acquired 280,000 common shares on December 12, 2025, from a Performance Stock Unit (PSU) award, which vested upon the U.S. FDA approval of Cardamyst (etripamil).
• Sold 133,054 common shares on December 15, 2025, at a weighted average price of $2.32, specifically to satisfy income tax liabilities incurred from the PSU vesting.
• Acquired 66,600 common shares on January 26, 2026, from a Restricted Stock Unit (RSU) award.
• Sold 34,523 common shares on January 26, 2026, at a weighted average price of $1.93, specifically to satisfy income tax liabilities incurred from the RSU vesting.
• Received an Employee Stock Option to purchase 280,000 common shares at an exercise price of $1.74 on December 12, 2025.
• The employee stock option will vest 50% on June 12, 2026, and the remaining 50% on December 12, 2026, contingent on continued service.
• The RSU award for 266,400 shares (of which 66,600 vested on Jan 26, 2026) vests in four equal annual installments, with subsequent vesting dates on January 26, 2027, 2028, and 2029.
• Beneficial ownership of common shares decreased from 583,721 to 482,744 following these reported transactions.

Sentiment

Score: 7

Explanation: The report indicates the successful FDA approval of Cardamyst, a major positive for the company, which triggered the vesting of performance-based equity for the CEO. While there were sales, they were explicitly for tax liabilities, which is a neutral event in itself, but the underlying vesting is positive.

Positives

• The vesting of 280,000 Performance Stock Units (PSUs) signifies the successful achievement of a major corporate milestone: U.S. FDA approval of Cardamyst (etripamil).
• The CEO received an Employee Stock Option to acquire 280,000 common shares at an exercise price of $1.74, aligning executive incentives with future company performance.
• The vesting of Restricted Stock Units (RSUs) for 66,600 shares reflects ongoing long-term incentive compensation for the CEO.

Negatives

• The CEO sold a total of 167,577 common shares (133,054 and 34,523) across two transactions, which reduced his direct beneficial ownership of common shares.
• The sales were executed at weighted average prices of $2.32 and $1.93, which may be below the company's historical highs, although these sales were for tax purposes.

Risks

• Future vesting of employee stock options and restricted stock units is contingent upon the Reporting Person continuing to provide service to the Issuer through each specified vesting date.

Future Outlook

The future outlook for Milestone Pharmaceuticals includes the continued vesting of executive equity awards, contingent on the CEO's ongoing service. The successful FDA approval of Cardamyst (etripamil) is a significant milestone that has triggered the vesting of performance-based compensation, indicating potential for future market entry and revenue generation.

Management Comments

• The PSU award vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
• Shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ('RSU') awards only, respectively.

Industry Context

The FDA approval of Cardamyst (etripamil) is a critical event for Milestone Pharmaceuticals, positioning the company to potentially enter the market with a new therapeutic. This achievement is a significant de-risking event for a biotechnology company, often leading to increased investor confidence and potential for revenue generation, aligning with broader trends of innovation and regulatory success in the pharmaceutical sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The CEO's increased direct ownership (post-tax sales) and significant option holdings align his interests with long-term shareholder value. The FDA approval is a major positive for the company's valuation.
• Employees: The vesting of equity awards for the CEO signals the company's progress and commitment to performance-based compensation, potentially boosting morale.
• Customers/Patients: FDA approval of Cardamyst means a new treatment option may become available.

Next Steps

• Continued vesting of the remaining 199,800 Restricted Stock Units in annual installments on January 26, 2027, 2028, and 2029.
• Vesting of the 280,000 Employee Stock Options in two tranches: 50% on June 12, 2026, and 50% on December 12, 2026.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Joseph Oliveto, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, FDA Approval, Cardamyst, Etripamil, Biotechnology, Pharmaceuticals, Executive Compensation, Sell-to-Cover